Rani Therapeutics (RANI)
0.84
0.00 (0.00%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)
August 21, 2026 6:59 AM - StreetInsider
Chardan Starts Rani Therapeutics (RANI) at Buy
August 18, 2026 7:12 AM - StreetInsider
Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:50 PM - SEC Filing
Form 10-Q Rani Therapeutics Holdin For: Jun 30
August 13, 2026 4:18 PM - SEC Filing
Rani Therapeutics Holdings, Inc. (RANI) Tops Q2 EPS by 1c
August 13, 2026 4:15 PM - StreetInsider
Form 8-K Rani Therapeutics Holdin For: Aug 13
August 13, 2026 4:13 PM - SEC Filing
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
August 13, 2026 4:05 PM - Globe NewsWire
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 10, 2026 8:00 AM - Globe NewsWire
Form 4 Rani Therapeutics Holdin For: Aug 03 Filed by: Gilson Michelle
August 4, 2026 8:52 PM - SEC Filing
Form 3 Rani Therapeutics Holdin For: Aug 01 Filed by: Gilson Michelle
August 4, 2026 8:49 PM - SEC Filing
Form 8-K Rani Therapeutics Holdin For: Aug 01
August 4, 2026 8:05 AM - SEC Filing
Rani Therapeutics names former Arcellx CFO to its board
August 4, 2026 8:00 AM - StreetInsider
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
August 4, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:43 AM - SEC Filing
Form 4 Rani Therapeutics Holdin For: Jul 21 Filed by: IMRAN MIR A
July 23, 2026 4:10 PM - SEC Filing
Form 4 Rani Therapeutics Holdin For: Mar 27 Filed by: Javadi Alireza
July 21, 2026 7:24 PM - SEC Filing
Form 4 Rani Therapeutics Holdin For: Jul 17 Filed by: Imran Talat
July 21, 2026 6:29 PM - SEC Filing
Form 4 Rani Therapeutics Holdin For: Dec 27 Filed by: Imran Talat
July 21, 2026 6:25 PM - SEC Filing
Form 4 Rani Therapeutics Holdin For: Jul 17 Filed by: Maestas Nicholas
July 21, 2026 4:51 PM - SEC Filing
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026 4:05 PM - Globe NewsWire
Form S-8 Rani Therapeutics Holdin
July 15, 2026 5:10 PM - SEC Filing
Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a
July 15, 2026 8:00 AM - StreetInsider
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
July 15, 2026 8:00 AM - Globe NewsWire
Rani Therapeutics and PegBio enter obesity drug collaboration
July 9, 2026 4:06 PM - StreetInsider
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
July 9, 2026 4:05 PM - Globe NewsWire
Form 3 Rani Therapeutics Holdin For: Jun 29 Filed by: Maestas Nicholas
July 8, 2026 4:05 PM - SEC Filing
Form 8-K Rani Therapeutics Holdin For: Jun 24
June 30, 2026 6:02 AM - SEC Filing
Rani Therapeutics names Nicholas Maestas as CFO
June 29, 2026 8:02 AM - StreetInsider
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
June 29, 2026 8:00 AM - Globe NewsWire
Full Article List
